RANK/RANK-L/OPG in Patients with Bone Metastases Treated with Anticancer Agents and Zoledronic Acid: A Prospective Study

Patients with solid cancer frequently develop bone metastases (BM). Zoledronic acid (Zometa(®), ZA), routinely used to treat patients with BM, acts on osteoclasts and also has antitumor properties. We aimed to assess the effect of ZA over time in novel bone turnover markers (RANK/receptor activator...

Descripción completa

Detalles Bibliográficos
Autores principales: Mercatali, Laura, Ricci, Marianna, Scarpi, Emanuela, Serra, Patrizia, Fabbri, Francesca, Ricci, Rossana, Liverani, Chiara, Zanoni, Michele, Zoli, Wainer, Maltoni, Roberta, Gunelli, Erica, Amadori, Dino, Ibrahim, Toni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Molecular Diversity Preservation International (MDPI) 2013
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3709696/
https://www.ncbi.nlm.nih.gov/pubmed/23702841
http://dx.doi.org/10.3390/ijms140610683

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3709696/
https://www.ncbi.nlm.nih.gov/pubmed/23702841
http://dx.doi.org/10.3390/ijms140610683

Ejemplares similares